Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Amyloid plaques are a key pathological hallmark of Alzheimer's disease (AD). The detection of amyloid plaques in the brain is important for the diagnosis of AD, as well as for following potential amyloid targeting therapeutic interventions. Our group has developed several contrast agents to detect amyloid plaques in vivo using magnetic resonance microimaging (µMRI) in AD transgenic mice, where we used mannitol to enhance blood brain barrier (BBB) permeability. In the present study, we used bifunctional ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, chemically coupled with Aβ1-42 peptide to image amyloid plaque deposition in the mouse brain. We coupled the nanoparticles to polyethylene glycol (PEG) in order to improve BBB permeability. These USPIO-PEG-Aβ1-42 nanoparticles were injected intravenously in AD model transgenic mice followed by initial in vivo and subsequent ex vivo μMRI. A 3D gradient multi-echo sequence was used for imaging with a 100 µm isotropic resolution. The amyloid plaques detected by T2*-weighted μMRI were confirmed with matched histological sections. The region of interest-based quantitative measurement of T2* values obtained from the in vivo μMRI showed contrast injected AD Tg mice had significantly reduced T2* values compared to wild-type mice. In addition, the ex vivo scans were examined with voxel-based analysis (VBA) using statistical parametric mapping (SPM) for comparison of USPIO-PEG-Aβ1-42 injected AD transgenic and USPIO alone injected AD transgenic mice. The regional differences seen by VBA in the USPIO-PEG-Aβ1-42 injected AD transgenic correlated with the amyloid plaque distribution histologically. Our results indicate that USPIO-PEG-Aβ1-42 can be used for amyloid plaque detection in vivo by intravenous injection without the need to co-inject an agent which increases permeability of the BBB. This technique could aid the development of novel amyloid targeting drugs by allowing therapeutic effects to be followed longitudinally in model AD mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies have co-injected intravenously with mannitol or polyethylene glycol to transiently open the BBB to amplify the abilities of USPIO coupled with Aβ (1-42) to detect Aβ in AD model mice.[22][23]”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 2×
“This transgenic line is based on the overexpression of both amyloid precursor protein mutations (APPK670N/M671L) and mutant presenilin-1 (PS1M146L) [36].”
BackgroundImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Weissleder, R., Elizondo, G., Wittenberg, J., Rabito, C. A., Bengele, H. H., & Josephson, L. (1990) · Radiology · doi:10.1148/radiology.175.2.2326474 · Cited by 1,028 · cited 1×
“USPIO are known to have much longer plasma K life of 24–36hr in humans [28,29] and ,2 hours in mice [30].”
Background2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity
Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991) · Brain Research · doi:10.1016/0006-8993(91)91553-d · Cited by 828 · cited 6×
“Another cause of potential concern with USPIO-PEG-Ab1-42 is the known toxicity of Ab1-42 at micromolar concentrations [39].”
BackgroundMethodInfluentialNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Computational anatomy with the SPM software
Ashburner, J. (2009) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2009.01.006 · Cited by 564 · cited 1×
“The steps involved in processing data were similar to that of human data processing and as we published previously [27,45].”
ResultWeissleder, R., Elizondo, G., Wittenberg, J., Lee, A. S., Josephson, L., & Brady, T. J. (1990) · Radiology · doi:10.1148/radiology.175.2.2326475 · Cited by 492 · cited 1×
“The plasma 1/2 life of USPIO has previously been shown to be , 2 hr in mice [52], while in humans the plasma K life is 24-36hr [28,29].”
BackgroundLong-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D'Angelo, J., Noel, J.-P., Georgin, D., Fattal, E., Andreux, J. P., & Couvreur, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010931127745 · Cited by 443 · cited 3×
“However, this technique still requires femoral co-injection of mannitol for CNS imaging as USPIO do not cross the intact BBB.”
BackgroundTargeting the brain with PEG–PLGA nanoparticles modified with phage-displayed peptides
Li, J., Feng, L., Fan, L., Zha, Y., Guo, L., Zhang, Q., Chen, J., Pang, Z., Wang, Y., Jiang, X., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.031 · Cited by 296
Self-citationDetection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging
Wadghiri, Y. Z., Sigurdsson, E. M., Sadowski, M., Elliott, J. I., Li, Y., Scholtzova, H., Tang, C. Y., Aguinaldo, G., Pappolla, M., Duff, K., et al. (2003) · Magnetic Resonance in Medicine · doi:10.1002/mrm.10529 · Cited by 280 · cited 9×
“In our prior studies we have used an intra-carotid or an intravenous route with a requirement for co-injections of mannitol to disrupt the BBB [13,19,26,27].”
BackgroundMethodResultInfluentialSelf-citationKoffie, R. M., Farrar, C. T., Saidi, L.-J., William, C. M., Hyman, B. T., & Spires-Jones, T. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111405108 · Cited by 260
Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., & Wisniewski, T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61715-4 · Cited by 258 · cited 1×
“Details of synthesis, purification, and sequence verification were described previously [27,37].”
MethodActive and passive immunotherapy for neurodegenerative disorders
Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250
Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy
Benveniste, H., Einstein, G., Kim, K. R., Hulette, C., & Johnson, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14079 · Cited by 238 · cited 1×
“Our studies corroborated reports by others using post-mortem AD brain tissue [20] and AD transgenic mouse brain tissue (ex vivo [21–23] and in vivo [22,24,25]).”
ResultMolecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging
Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., Borowski, B. J., & Jack, C. R. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0550 · Cited by 215
Jack, C. R., Garwood, M., Wengenack, T. M., Borowski, B., Curran, G. L., Lin, J., Adriany, G., Gröhn, O. H. J., Grimm, R., & Poduslo, J. F. (2004) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20266 · Cited by 199 · cited 1×
“Our studies corroborated reports by others using post-mortem AD brain tissue [20] and AD transgenic mouse brain tissue (ex vivo [21–23] and in vivo [22,24,25]).”
ResultMaggio, J. E., Stimson, E. R., Ghilardi, J. R., Allen, C. J., Dahl, C. E., Whitcomb, D. C., Vigna, S. R., Vinters, H. V., Labenski, M. E., & Mantyh, P. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5462 · Cited by 196 · cited 1×
“Ab peptides are known to have high affinity binding to each other, in particular monomeric Ab to deposited, aggregated Ab; hence, coating USPIO nanoparticles with monomeric Ab1-42 is expected to target the particles to amyloid plaques, as demonstrated in prior publications [13,18,19,27,38].”
ResultPhase I clinical evaluation of a new iron oxide MR contrast agent
McLachlan, S. J., Morris, M. R., Lucas, M. A., Fisco, R. A., Eakins, M. N., Fowler, D. R., Scheetz, R. B., & Olukotun, A. Y. (1994) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880040313 · Cited by 194 · cited 2×
“USPIO are known to have much longer plasma K life of 24–36hr in humans [28,29] and ,2 hours in mice [30].”
BackgroundSadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167
Calvo, P., Gouritin, B., Villarroya, H., Eclancher, F., Giannavola, C., Klein, C., Andreux, J. P., & Couvreur, P. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01967.x · Cited by 164
Amyloid-β immunisation for Alzheimer's disease
Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155
Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63355-x · Cited by 154
Self-citationSawiak, S. J., Wood, N. I., Williams, G. B., Morton, A. J., & Carpenter, T. A. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.016 · Cited by 149 · cited 1×
“VBA analysis was performed using MATLAB 9 (the MathWorks, Natick, MA) and SPM5 (Wellcome Trust Center for Neuroimaging, University College London, UK) with SPMMouse toolbox [44].”
MethodIn Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice
Jack, C. R., Wengenack, T. M., Reyes, D. A., Garwood, M., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., Holasek, S. S., Adriany, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2588-05.2005 · Cited by 148 · cited 1×
“Our studies corroborated reports by others using post-mortem AD brain tissue [20] and AD transgenic mouse brain tissue (ex vivo [21–23] and in vivo [22,24,25]).”
ResultAβ aggregation and possible implications in Alzheimer's disease pathogenesis
Bharadwaj, P. R., Dubey, A. K., Masters, C. L., Martins, R. N., & Macreadie, I. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00609.x · Cited by 146
Yasuhara, T., Hara, K., Maki, M., Xu, L., Yu, G., Ali, M. M., Masuda, T., Yu, S. J., Bae, E. K., Hayashi, T., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00671.x · Cited by 144
Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., & Van der Linden, A. (2005) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20385 · Cited by 138 · cited 1×
“Our studies corroborated reports by others using post-mortem AD brain tissue [20] and AD transgenic mouse brain tissue (ex vivo [21–23] and in vivo [22,24,25]).”
ResultYang, J., Zaim Wadghiri, Y., Minh Hoang, D., Tsui, W., Sun, Y., Chung, E., Li, Y., Wang, A., de Leon, M., & Wisniewski, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.023 · Cited by 135 · cited 10×
“The potential neurotoxicity of USPIO-PEG-Ab1-42 was assessed in a human neuroblastoma cell line (SK-N-SH) using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium (MTS) Cell Proliferation Assay (Promega, Madison, WI) and compared to the known toxicity of Ab142 [39,40], using me…”
BackgroundMethodResultInfluentialSelf-citationScholtzova, H., Wadghiri, Y. Z., Douadi, M., Sigurdsson, E. M., Li, Y., Quartermain, D., Banerjee, P., & Wisniewski, T. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21713 · Cited by 120
Self-citationMcCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J., & Fu, H. (2009) · Gene Therapy · doi:10.1038/gt.2009.85 · Cited by 105 · cited 1×
“Although this is a well studied and effective means of increasing the permeability of the BBB, allowing the CNS delivery of various agents such as neurotrophic factors, viral vectors and USPIO [49–51], it has a short duration of action (,15 min in rodents) [50] and it is associated with some toxicity.”
BackgroundKu, S., Yan, F., Wang, Y., Sun, Y., Yang, N., & Ye, L. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.006 · Cited by 92
Self-citationUses of Nanoparticles for Central Nervous System Imaging and Therapy
Provenzale, J. M., & Silva, G. A. (2009) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1590 · Cited by 89 · cited 3×
“However, this technique still requires femoral co-injection of mannitol for CNS imaging as USPIO do not cross the intact BBB.”
BackgroundAmyloid proteins : methods and protocols
Sigurdsson, E. M., Calero, M., & Gasset, M. (2005) · Cited by 87
Murine models of Alzheimer's disease and their use in developing immunotherapies
Wisniewski, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 81 · cited 1×
“not subject to amyloid deposition in this mouse model [12,36].”
BackgroundRamakrishnan, M., Kandimalla, K. K., Wengenack, T. M., Howell, K. G., & Poduslo, J. F. (2009) · Biochemistry · doi:10.1021/bi900523q · Cited by 81
Braakman, N., Matysik, J., van Duinen, S. G., Verbeek, F., Schliebs, R., de Groot, H. J. M., & Alia, A. (2006) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20675 · Cited by 77
Three‐dimensional, in vivo MRI with self‐gating and image coregistration in the mouse
Nieman, B. J., Szulc, K. U., & Turnbull, D. H. (2009) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21945 · Cited by 68 · cited 1×
“For in vivo mMRI a modified 3D spoiled gradient recalled multiecho (SPGRME) sequence was used to acquire an additional selfgated signal on the readout dephasing gradient within each TR [41].”
MethodA non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice
Sigurdsson, E. M., Wadghiri, Y. Z., Mosconi, L., Blind, J. A., Knudsen, E., Asuni, A. A., Scholtzova, H., Tsui, W. H., Li, Y., Sadowski, M. J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.018 · Cited by 68
Self-citationDubois, A., Hérard, A., Delatour, B., Hantraye, P., Bonvento, G., Dhénain, M., & Delzescaux, T. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.074 · Cited by 61 · cited 1×
“05 (uncorrected for multiple comparisons) to indicate statistical significance for individual voxels, with a minimum cluster size of 500 voxels as previously reported for rodent VBA analysis[46,47].”
Vaccination as a Therapeutic Approach to Alzheimer's Disease
Wisniewski, T., & Boutajangout, A. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20156 · Cited by 51
Self-citationPotential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease
Larbanoix, L., Burtéa, C., Laurent, S., LEUVEN, F. V., Toubeau, G., Elst, L. V., & Müller, R. N. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.021 · Cited by 49
Visualizing the Future: Enhancing Neuroimaging with Nanotechnology
Winer, J. L., Kim, P. E., Law, M., Liu, C. Y., & Apuzzo, M. L. J. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.02.016 · Cited by 49 · cited 4×
“USPIO are known to have much longer plasma K life of 24–36hr in humans [28,29] and ,2 hours in mice [30].”
BackgroundInfluentialMolecular targeting of Alzheimer's amyloid plaques for contrast‐enhanced magnetic resonance imaging
Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., Borowski, B. J., & Jack, C. R. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.81.s1.20_5.x · Cited by 43
Dubois, A., Hérard, A., Flandin, G., Duchesnay, É., Besret, L., Frouin, V., Hantraye, P., Bonvento, G., & Delzescaux, T. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.11.054 · Cited by 37 · cited 1×
“05 (uncorrected for multiple comparisons) to indicate statistical significance for individual voxels, with a minimum cluster size of 500 voxels as previously reported for rodent VBA analysis[46,47].”
Oude Engberink, R. D., Blezer, E. L. A., Dijkstra, C. D., van der Pol, S. M. A., van der Toorn, A., & de Vries, H. E. (2010) · NMR in Biomedicine · doi:10.1002/nbm.1536 · Cited by 34 · cited 1×
“PEG) do not cross an undamaged BBB [27,29,48].”
BackgroundMagnetic Resonance Imaging of Amyloid Plaques in Transgenic Mouse Models of Alzheimers Disease
Chamberlain, R., M. Wengenack, T., F. Poduslo, J., Garwood, M., & R. Jack, C. (2011) · Current Medical Imaging Reviews · doi:10.2174/157340511794653522 · Cited by 26
Detecting Amyloid-β Plaques in Alzheimer’s Disease
Baltes, C., Princz-Kranz, F. L., Rudin, M., & Mueggler, T. (2010) · Methods in molecular biology · doi:10.1007/978-1-61737-992-5_26 · Cited by 23
In Vivo Magnetic Resonance Imaging of Amyloid-β Plaques in Mice
Wadghiri, Y. Z., Hoang, D. M., Wısnıewskı, T., & Sigurdsson, E. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-551-0_30 · Cited by 23
Self-citationMolecular Neuroimaging in Alzheimer's Disease
Matsuda, H., & Imabayashi, E. (2011) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.005 · Cited by 22
Magnetic Resonance Imaging of Amyloid Plaques in Transgenic Mice
Wadghiri, Y. Z., Sigurdsson, E. M., Wısnıewskı, T., & Turnbull, D. H. (2005) · Humana Press eBooks · doi:10.1385/1-59259-874-9:365 · Cited by 16
Self-citationThe Living Brain and Alzheimer’s Disease
Hyman, B. T. (2004) · Springer eBooks · doi:10.1007/978-3-642-59300-0_3 · Cited by 8
In Vivo Magnetic Resonance of Amyloid Plaques in Alzheimer’s Disease Model Mice
Sigurdsson, E. M., Wadghiri, Y. Z., Sadowski, M. J., Elliott, J. I., Li, Y., Scholtzova, H., Tang, C. Y., Aguinaldo, G., Duff, K., Turnbull, D. H., et al. (2004) · Springer eBooks · doi:10.1007/978-3-642-59300-0_5 · Cited by 7 · cited 1×
“Serial coronal sections (40 mm) were cut and every fifth section were stained with a combination of 6E10 (epitope Ab3-8) and 4G8 (epitope Ab17-24), both monoclonal anti-Ab antibodies (Covance, Emeryville, CA), as previously described [13,16,18,26].”
MethodSelf-citation
Research works printed but not linked: 1
- M Sadowski, 2006, Blocking the apolipoproteinE/Amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice, Proc Natl Acad Sci (USA), 103(49), 18787
Cited by
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,603
Cheng, K. K., Chan, P. S., Fan, S., Kwan, S. M., Yeung, K. L., Wáng, Y.-X. J., Chow, A. H. L., Wu, E. X., & Baum, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.005 · Cited by 293
“The authors have introduced a new nano formulation using a less toxic fragment of Ab peptide [23] and co-linking with polyethylene glycol (PEG) to replace co-injection of mannitol [24].”
BackgroundMethodResultMagnetic iron oxide nanoparticles for brain imaging and drug delivery
Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114822 · Cited by 245
Wallyn, J., Anton, N., & Vandamme, T. F. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110601 · Cited by 207
“In this way, magnetic NPs have already been involved into various biomedical applications including dental applications [15], and illnesses local treatment like neurological diseases [16] and cardiovascular diseases [13].”
BackgroundNiu, X., Chen, J., & Gao, J. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.09.005 · Cited by 190
“[82] Wadghiri YZ , Li J , Wang J , et al.”
Background
Metadata
- Authors
- Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., de Leon, M., & Wisniewski, T.
- Affiliations
- New York University (US)
- Tianjin Huanhu Hospital (CN)
- Ocean NanoTech (United States) (US)
- Corresponding author
- Wadghiri, Youssef Zaim
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-02-27
- Volume
- 8
- Issue
- 2
- Pages
- e57097
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3584149
- OpenAlex
- W2024542897
- Cited by
- 114
- References
- 54
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 11 · 2021: 2 · 2020: 8 · 2019: 11 · 2018: 11 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 15 · 2013: 3
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Health Assistance Foundation (A2008-155)
- Tianjin Science and Technology Committee
- National Institutes of Health
- National Institute on Aging (AG20245, P30AG008051, R01AG020245)
- National Cancer Institute (P30CA016087)
- National Institute of Neurological Disorders and Stroke (NS073502, R01NS073502)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
- Keywords
- amyloid plaques, Alzheimer's disease, ultrasmall superparamagnetic iron oxide, blood-brain barrier permeability, polyethylene glycol, anti-amyloid therapy, T2 contrast, transgenic mouse model, ex vivo imaging
- MeSH terms
- Alzheimer Disease, Animals, Brain, Contrast Media, Disease Models, Animal, Magnetic Resonance Imaging, Mice, Transgenic, Amyloid beta-Peptides, Mice, Magnetite Nanoparticles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.